// App-Quantinova.ai

507 : PALOMA-2: Primary Results From a Phase III Trial of Palbociclib Plus Letrozole Compared With Placebo Plus Letrozole in Postmenopausal Women With ER+/HER2- Advanced Breast Cancer

Researchers

Presenter

  • Richard S. Finn

Principal Investigators

  • Miguel Martin

  • Hope S. Rugo

  • Stephen E. Jones

  • Seock-Ah Im

  • Karen A. Gelmon

  • Nadia Harbeck

  • Oleg N. Lipatov

  • Janice Maria Walshe

  • Stacy L. Moulder

  • Eric Roland Gauthier

  • Dongrui (Ray) Lu

  • Sophia Randolph

  • Veronique Dieras

  • Dennis J. Slamon

Medical Centers

  • David Geffen School of Medicine, Santa Monica, CA

  • Hospital Gregorio Maranon, Universidad Complutense, Madrid, Spain

  • University of California, San Francisco, San Francisco, CA

  • US Oncology Research, and The Woodlands, The Woodlands, TX

  • BC Cancer Agency, Vancouver, BC, Canada

  • Brustzentrum der Universitat Munchen (LMU), Munich, Germany

  • Adelaide and Meath Hospital, Dublin, Ireland

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Pfizer Oncology, La Jolla, CA

  • Pfizer Inc, San Diego, CA

  • Institut Curie, Paris Cedex, France

  • University of California, Los Angeles, Los Angeles, CA

Locations

  • Ireland

  • Canada

  • Spain

  • Germany

  • United States

  • France

Companies

  • Pfizer Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Cardiac phospholamban

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Palbociclib

  • Letrozole

Outcome

  • Positive

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved